1017 Views

Dr (Prof) DK Agarwal, New Delhi 11 January 2018

The most common approach of treatment of patients with nondialysis-dependent (ND-CKD) is the use of erythropoiesis-stimulating agents (ESA) and oral iron treatment.
A prospective, single arm and single center study including adult patients with ND-CKD was conducted to evaluate the effect of a switch from oral iron to intravenous ferric carboxymaltose (IV FCM).
The study results showed that among patients with ND-CKD and stable or normal/borderline hemoglobin(HB), switching from oral iron to IV FCM was associated with significant improvement in hematological and iron parameters and a significant reduction in ESA dose requirements.
The study results did not report any adverse events related to the use of FCM.
The results of the trial suggested that a single IV FCM dose of 1,000 mg iron was effective in reducing monthly ESA dose requirements along with associated treatment costs; maintaining recommended target Hb levels and increasing the iron parameters to target levels in patient with ND-CKD who had 6 months oral iron treatment before switching to FCM.

Already registered?

EXPLORE!

2 simple steps!